Floatz logo

REGADENOSON

Asthma

Wake Forest University Health SciencesSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Asthma cohort.

Asset / SponsorPhaseRating
Budesonide
New York City Health and Hospitals Corporation
Phase 4BBB
SALMETEROL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 4BBB
Flixotide
GlaxoSmithKline
Phase 4BBB
Montelukast
Kafrelsheikh University
Phase 4BBB
Mirabegron
Kafrelsheikh University
Phase 4BB

View all 48 →

Same molecule, other indications

REGADENOSON is also rated in:

sickle cell diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
anaplastic oligodendrogliomaDormant
CC
Indicative ·
43 / 100
View asset →
malignant gliomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →